Company intelligence / Profile preview
DS Biopharma
Dublin, Leinster, Irelanddsbiopharma.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 2
01
Overview
Positive results from a study where continued treatment with 5% DS107 cream showed efficacy; two abstracts accepted at the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference
- Therapeutic areas
- GastroenterologyPulmonologyMetabolic DisordersEndocrinologyDermatology
- Modalities
- Bioactive lipids
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Nuvothera (option to license rights to develop and commercialize EPADILIN in the US)
Beyond the preview
Go deeper on DS Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS Biopharma.